(847) 562-5868Toll Free: (855) TMS-MIND or (855) 867-6463
News

Leading National TMS provider—more locations, more doctors, more experience, more success!
Jul 10
Cheryl Oblander, TheraMind SVP

Cheryl Tama Oblander, J.D., MT (ASCP), TheraMind Services, Inc. Senior Vice President

Vernon Hills, IL, July 10, 2019 – TheraMind Services, Inc., a leading provider of advanced health care treatment for neurological and behavioral disorders, is pleased to announce that Cheryl Tama Oblander, J.D., MT (ASCP) has joined their Executive Team as Senior Vice-President, Associate General Counsel & Assistant Secretary, overseeing the company’s legal functions from clinical compliance to business development.

“Cheryl’s experience spanning clinical and legal leadership is uniquely suited to our mission to improve the lives of patients by offering the most advanced healthcare alternatives for individuals dealing with anxiety, depression, and other mood disorders,” said TheraMind Services, Inc. President, Mark Heatwole. “Cheryl’s expertise benefits our clients and the outstanding clinical services our team is able to provide, as we expand the company to meet the demand from consumers and health care providers for access to rapidly increasing options for proven effective treatments.”

Prior to joining TheraMind, Cheryl was a partner and practiced law with two large international law firms, representing clients in a wide variety of industries, including health care providers, pharmaceuticals and medical device manufacturers. Her practice areas included federal and state employment law, employee benefits, fiduciary duties, trade secrets, restrictive covenants, executive employment and compensation agreements, hiring, discipline and terminations, employment policies, legal compliance, internal investigations and employment aspects of mergers, acquisitions and reorganizations. Cheryl was lead counsel of record in more than 100 cases, including every level of litigation from single-plaintiff matters to large scale complex and class actions. Her practice spanned the country and she is admitted to courts in multiple jurisdictions, including the United States Supreme Court.

With Theramind, Cheryl combines her many years of legal practice with her earlier health care experience. Prior to attending Loyola University Chicago School of Law, she had a decade of experience providing direct patient services. She had trained at Michael Reese Hospital and Medical Center in its Medical Technology Program, received her Medical Technology license (American Society for Clinical Pathology), and became Senior Medical Technologist in the Department of Biochemistry. In that role, she was responsible for routine and emergency analyses of patient specimens for complex chemical and biological components, performed advanced trouble shooting for state of the art analytical equipment, evaluated test results, developed and modified clinical laboratory procedures, and established and monitored programs to ensure the accuracy of test results and to maintain compliance with all laboratory accrediting requirements.

“I am excited to join TheraMind Services, Inc., where I will combine my legal and medical experiences working with an excellent team to successfully navigate the landscape of health care advancements, compliance and coverage in this important and rapidly expanding field,” said Cheryl.

About TheraMind Services, Inc.

TheraMind Services, Inc. is committed to improving the lives of patients by providing physicians with the most advanced therapeutic, non-drug alternatives for treating a broad variety of neurological and behavioral disorders. Our doctors successfully treat patients suffering from treatment-resistant depression (TRD), Major Depressive Disorder (MDD), Anxiety Disorder, Post-Traumatic Stress Disorder (PTSD), Bipolar Disorder, Obsessive Compulsive Disorder (OCD) and other mood disorders. The Center also routinely treats patients suffering from a variety of neurological disorders including Chronic Pain, Fibromyalgia, Migraines, Tinnitus, Stroke-related disorders, Concussion and TBI, and others.

We employ advanced diagnostic technologies such as fMRI and genetic testing to assist our physicians and referring medical professionals in assessing patient needs. Our highly-trained staff members are committed to providing outstanding supporting services to referring medical professionals, their patients and the patients’ family members. For more information about TheraMind Services, Inc. and our TheraMind Centers, please visit https://tmsmind.com/.


Jul 09

New TheraMind© Center of Chicago located in landmark Willoughby Tower

Chicago, IL, July 10, 2019 — TheraMind Services, Inc., a leading provider of advanced health care treatments for neurological and behavioral disorders, is pleased to announce the opening of their new Chicago outpatient treatment center, which is centrally located in the Historic Michigan Avenue District, at 8 S. Michigan Avenue in the landmark Willoughby Tower. The 36-story Willoughby Tower, located just across from Grant Park and “The Bean,” is home to an array of renowned regional healthcare and nonprofit organizations.

Medical direction at the new Center is provided by Dr. Dawna Gutzmann, a graduate of Northwestern University’s Feinberg School of Medicine, who has over 20 years of experience treating patients with mood disorders and who has been affiliated with TheraMind Services, Inc. at the TheraMind Center of Skokie since 2014.

Treatment options available at the new TheraMind Center of Chicago include, in addition to traditional psychiatric services, Transcranial Magnetic Stimulation (TMS), a non-invasive, FDA-approved, high tech therapy which uses rapid magnetic pulses to stimulate nerve cells in the area of the brain known to control mood. TMS treatments are outpatient procedures requiring no anesthesia or sedation and are covered by most healthcare insurers and Medicare for depression.

“Our expansion into major cities like Chicago is being driven by demand for non-drug alternatives for individuals dealing with anxiety, depression, and other mood disorders,” said TheraMind Services, Inc. President Mark Heatwole. “TMS has been demonstrated to be a highly effective therapy for treating patients suffering from depression which is not adequately managed by antidepressants. It’s not surprising, therefore, that patients are seeking the innovative medical solutions TheraMind is known to deliver. In the greater Chicago area, we serve the north and northwestern communities through our Centers in Skokie and Vernon Hills and we are delighted to now be able to offer our most advanced behavioral therapies to the downtown Chicago community.”

About TheraMind Services, Inc.

TheraMind Services, Inc. is committed to improving the lives of patients by providing the most advanced therapeutic, non-drug alternatives for treating a broad variety of neurological and behavioral disorders. Our doctors successfully treat patients suffering from Major Depressive Disorder (MDD), Anxiety Disorder, Post-Traumatic Stress Disorder (PTSD), Bipolar Disorder, Obsessive Compulsive Disorder (OCD) and other mood disorders. Our treatment centers also routinely treat patients suffering from a variety of neurological disorders including chronic pain, fibromyalgia, migraines, tinnitus, stoke-related disorders, concussion and TBI, and others. We employ advanced diagnostic technologies such as fMRI and genetic testing to assist our physicians and referring medical professionals in assessing patient needs. Our highly-trained staff members are committed to providing outstanding supporting services to referring medical professionals, their patients and the patients’ family members.


Oct 01

Already FDA-approved to treat major depression and migraines, TMS can now be marketed as a treatment for obsessive compulsive disorder

Santa Barbara, Calif., September 21, 2018 – Transcranial Magnetic Stimulation (TMS) therapy is rapidly growing in popularity as a treatment for many neurological and mood disorders, and the cutting-edge medical technology recently reached another major milestone that should accelerate demand for the non-drug treatment option.

The US Food and Drug Administration (FDA) announced in August that it had approved TMS to be marketed as a treatment for obsessive compulsive disorder (OCD). The FDA previously permitted marketing TMS as a treatment for major depression in 2008 and expanded the use to include TMS for treating pain associated with certain migraine headaches in 2013.

“This is another exciting moment for everyone involved in TMS therapy, and provides additional validation for the effectiveness of TMS,” said Mark Heatwole, President of TheraMind Services, Inc. “This is an important step in the positive momentum toward making TMS a universally available treatment for those suffering from neurological and other mood disorders.”

Click here to read the full news release from the FDA.

To learn more about TMS therapy and other treatments offered at the TheraMind Center of Santa Barbara, call (805) 845-4455 or visit tmsmind.com/santabarbara-ca.

About the TheraMind Center of Santa Barbara

The TheraMind Center of Santa Barbara is committed to improving the lives of patients by providing physicians with the most advanced therapeutic, non-drug alternatives for treating a broad variety of neurological and behavioral disorders. Our doctors successfully treat patients suffering from treatment-resistant depression (TRD), Major Depressive Disorder (MDD), Anxiety Disorder, Post-Traumatic Stress Disorder (PTSD), Bipolar Disorder, Obsessive Compulsive Disorder (OCD) and other mood disorders. The Center also routinely treats patients suffering from a variety of neurological disorders including Chronic Pain, Fibromyalgia, Migraines, Tinnitus, Stroke-related disorders, Concussion and TBI, and others.

We employ advanced diagnostic technologies such as fMRI and genetic testing to assist our physicians and referring medical professionals in assessing patient needs. Our highly-trained staff members are committed to providing outstanding supporting services to referring medical professionals, their patients and the patients’ family members.


Oct 01

Dr. Sheldon Jordan, a leader in neuroimaging, discusses Transcranial Magnetic Stimulation with doctors, nurses, and members of the community on Wednesday, August 8 at Santa Barbara Cottage Hospital

Santa Barbara, Calif., August 16, 2018 – Dr. Sheldon Jordan, MD, FAAN is widely recognized as a leader in brain imaging using functional magnetic resonance imaging (fMRI) and Transcranial Magnetic Stimulation (TMS) targeting techniques to treat Major Depressive Disorder and other neurological and psychological disorders.

On Wednesday, August 8th, Dr. Jordan presented to a group of doctors, nurses, and community members at Santa Barbara Cottage Hospital as part of their monthly Psychiatric Grand Rounds, hosted by the Department of Psychiatry and Addiction Medicine at Santa Barbara Cottage Hospital. These presentations are meant to introduce clinicians to recent advances that enhance treatment and provide a forum for discussion of topics that strengthen the relationship of psychiatry and addiction medicine to the broader Santa Barbara community.

A group of about 50 people gathered in Santa Barbara Cottage Hospital’s Burtness Auditorium to learn about TMS and how it can be used to treat depression, anxiety, and other mood disorders. TMS therapy, an FDA-cleared, non-invasive treatment, employs MRI-strength magnetic impulses targeted to specific regions of the brain involved in the regulation of mood.

Dr. Jordan touched on the fact that every person’s situation is unique, and that depression often works in combination with a number of other disorders, such as anxiety and rumination.

“Depression isn’t a static problem,” said Dr. Jordan. “It’s something that worsens over the course of a person’s life. All heads are different and they can’t all be treated the same way. One-size-fits-all depression treatment doesn’t work.”

Dr. Jordan has been in private practice in West Hollywood and Santa Monica since 1981, with an emphasis on interventional pain management, neuroimaging, clinical neurophysiology, and sports neurology. He currently oversees the administration of TMS therapy for patients at the TheraMind Center of Santa Monica.

To learn more about TMS therapy and other treatments offered at the TheraMind Center of Santa Barbara, call (805) 845-4455 or visit tmsmind.com/santabarbara-ca.

About the TheraMind Center of Santa Barbara

The TheraMind Center of Santa Barbara is committed to improving the lives of patients by providing physicians with the most advanced therapeutic, non-drug alternatives for treating a broad variety of neurological and behavioral disorders. Our doctors successfully treat patients suffering from treatment-resistant depression (TRD), Major Depressive Disorder (MDD), Anxiety Disorder, Post-Traumatic Stress Disorder (PTSD), Bipolar Disorder, Obsessive Compulsive Disorder (OCD) and other mood disorders. The Center also routinely treats patients suffering from a variety of neurological disorders including Chronic Pain, Fibromyalgia, Migraines, Tinnitus, Stroke-related disorders, Concussion and TBI, and others.

We employ advanced diagnostic technologies such as fMRI and genetic testing to assist our physicians and referring medical professionals in assessing patient needs. Our highly-trained staff members are committed to providing outstanding supporting services to referring medical professionals, their patients and the patients’ family members.


Nov 08

The National Institute of Mental Health is currently recruiting participants for a clinical study to see if using functional magnetic resonance imaging (fMRI) to guide repetitive transcranial magnetic stimulation (rTMS) helps locate the best area for treatment and to explore whether the efficacy of such treatment can enhanced through cognitive behavioral therapy (CBT). Eligible participants are adults ages 18 to 65 with a major depressive disorder and current depression. The study is composed of three phases: Phase 1 will be 4 visits in 1 week where the fMRI will be done along with certain brain activity testing; Phase 2 will be conducted over 6 – 7 weeks where participants will do 30 TMS sessions combined with computer generated CBT and repeat the Phase 1 tests; and, Phase 3 will be 3 visits over three months to rate participants’ depression symptoms. A complete description of the study can be found at clinicaltrials.gov.


Nov 08

Low Level Light (or Laser) Therapy, also sometimes referred to as “Phototherapy”, was the subject of a recent study that sought to compare the effects of red and infrared LLLT on skeletal muscle fatigue in humans. A randomized double-blind placebo-controlled crossover trial was performed on 10 healthy male volunteers. They were treated with active red LLLT (660nm) and active infrared LLLT (830nm) or an identical placebo at identical locations before exercise. The study concluded that both red LLLT and infrared LLLT therapy were significantly better in delaying muscle fatigue than placebo and, further, that there was no significant difference in result between the two active LLLT therapies. A full discussion of the study parameters and results can be found at www.ncbi.nlm.nih.gov.


Nov 08

Hyperbaric Oxygen Therapy (HBOT) was recently used in combination with metabolically supported chemotherapy (MSCT), ketogenic diet (KD) and hyperthermia (HT) to treat a 29-year old patient with Stage IV Triple-Negative Breast Cancer (TNBC). The patient was admitted to the hospital in Istanbul, Turkey in October, 2016, where a whole body PET-CT scan revealed a primary tumor in her left breast, multiple left pectoral and axillary lymph nodes, multiple widespread liver masses, and an upper left nodular abdominal lesion. Following a treatment protocol consisting of MSCT, KD HT and HBOT, a follow-up full body PET-CT scan in February, 2017 showed a complete therapeutic response with no evidence of abnormal FDG uptake. The treatment protocol above was continued until April, 2017 when the patient underwent a mastectomy which revealed a complete pathological response consistent with the PET-CT scan imaging. The complete report can be seen at: www.ncbi.nlm.nih.gov.


Apr 03

Transcranial magnetic stimulations (TMS) is featured in this month’s Oprah “O” Magazine titled, “A Twinge of Relief”. The article notes the 2008 FDA approval of TMS for mildly treatment-resistant depression and outlines standard treatment information by Dr. Stephen Taylor, MD and professor of psychiatry at the University of Michigan.

Dr. Taylor describes a typical therapy treatment by stating that “magnetic coils are placed on one side of the patient’s head to induce electrical currents that cause neurons to discharge—delivering pure energy into the brain.” He highlighted that therapy typically involves four to six weeks of 30- to 40-minute sessions administered five times a week in a doctor’s office. The positive, he mentions, is that TMS can be as effective as taking antidepressants but with fewer side effects. Dr. Taylor closes by stating, “the idea that we’re able to ameliorate depression with a magnet is a pretty cool thing.”


Jun 10

With May being Depression Awareness month, Greatday Houston, a daily KHOU talk show, featured NeuroStar TMS Depression Therapy on their May 18, 2015 Medical Monday series. Guests included Dr. Cathy Hart, Medical Director of a local TMS Therapy Center, and a Greatday Houston viewer who had tried this new depression treatment. Dr. Hart explained how magnetic therapy works, a no pills and no surgery depression treatment, while the guest explained her struggles with depression and her TMS Therapy success story. View the show.


May 14

This month, Fox 40, WFTX-TV in Fort Myers, Florida featured special news coverage on TMS therapy and one women’s life changing experience. The special report was called “Latest Technology ‘Zaps’ Depression”. Diagnosed at 13 with medical depression, Jessica felt isolated, constant sadness and contemplated suicide. She wanted to share her story of struggle and success to hopefully inspire others. After the day-to-day struggles and trying so many different medications, her doctor felt she was a good candidate for TMS therapy. Jessica mentioned that the beauty of the treatment was that it didn’t hurt, there were no side affects and it truly changed her life. Read or listen to her story.


Feb 28

NewsChannel 3 in Virginia recently featured a medical segment on treating depression without drugs. The special, “Can Depression Be Treated Without Drugs?” documented a 35-year old patient and local newspaper reporter from Peninsula who suffered from depression most of her adult life, including battles with social anxiety, phobia and paranioa. Finally, she discovered a doctor in Virginia Beach who was using TMS therapy. After six weeks of weekly treatments, she was able to get back to her normal life and do one of her favorite things again, writing. Read or listen to the whole story.


Jan 16

WOSU, an Ohio State University radio station, recently featured Transcranial Magnetic Stimulation, TMS, as a new depression treatment option that is showing success among some who have struggled with mental illness for years. The show and article highlights one patient’s experience with TMS therapy after suffering from depression for over 13 years. Mr. Jefferys used drug therapy and counseling for years but at one point attempted suicide. Finally, at 48, he learned about TMS therapy. Read or listen to his TMS success story.


Jan 04

Transcranial Magnetic Stimulation therapy continues to receive great media exposure as more and more success stories are shared. A recent December 15, 2014 Us News and World Report article detailed one patient’s success story and how transcranial magnetic stimulation, or TMS, saved her life. The article also describes the origin of TMS, how TMS is different from other brain-stimulation therapies, what the treatment is like, possible side effects and those most suited for this type of depression treatment. Read the article.


1 2 3 5